Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib in HCC Patients at High Risk of Post-Surgery Recurrence
NCT03945799Phase 2Terminated
- Sponsor
- Zhejiang University
- Start
- Apr 2019
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib in hepatocellular carcinoma (HCC), sponsored by Zhejiang University. Primary endpoint: Disease-Free Survival at 1 year. Started Apr 2019; status: terminated.
02
Drugs
anlotinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03945799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03945799.